Tesaro Inc

Tesaro — Q3 2013 Earnings Presentation

24 slides from Tesaro's earnings presentation, Nov 7, 2013

  1. Slide 1: Third-Quarter Operating Results

    Third-Quarter Operating Results November 7, 2013

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are forward-looking statements reflecting the current beliefs and expectations of management. Forward-looking statements are sometimes identified by words such as “plan,” “may,

  3. Slide 3: Lonnie Moulder, Chief Executive Officer

    Lonnie Moulder Chief Executive Officer

  4. Slide 4: Ted English, VP Finance & Administration

    Ted English Vice President, Finance & Administration

  5. Slide 5: Q3 2013 Financial Results

    Q3 2013 Financial Results Three Months Ended September 30, 2013 Three Months Ended September 30, 2012 Expenses: Research & Development $22,163 $11,876 General & Administrative 4,503 1,736 Acquired In-process R&D 1,940 -- Total Expenses 28,606 13,612 Loss from Operations (28,606) (13,612) Interest In

  6. Slide 6: Mary Lynne Hedley, Ph.D., President

    Mary Lynne Hedley, Ph.D. President

  7. Slide 7: A Balanced Portfolio of Product Candidates

    MEC: Moderately Emetogenic Chemotherapy; HEC: Highly Emetogenic Chemotherapy; CINV: Chemotherapy-Induced Nausea & Vomiting A Balanced Portfolio of Product Candidates Compound Indication Pre-clinical Phase 1 Phase 2 Phase 3 Rolapitant Oral (NK-1 receptor antagonist) CINV in HEC treated patients CINV

  8. Slide 8: Development Programs Update

    SARC: Sarcoma Alliance for Research through Collaboration Development Programs Update Phase 3 NOVA trial continues to enroll patients Phase 3 BRAVO trial now screening patients Collaborating with SARC for Ewing’s sarcoma Niraparib Initial Phase 1 data presented at the European Cancer Congress and 15

  9. Slide 9: Ovarian Design and Objectives

    Ovarian Design and Objectives 360 patients with high grade serous ovarian cancer (HGSOC) Platinum sensitive, relapsed Two independent cohorts: gBRCAmut and non-gBRCAmut Overview Randomized, international study Each cohort is independently randomized 2:1 niraparib to placebo; powered separately Daily

  10. Slide 10: Breast Design and Objectives

    Breast Design and Objectives ~300 patients with gBRCAmut and advanced/metastatic Prior anthracycline/taxane Up to 2 treatments for advanced/metastatic disease Overview Randomized, international study Independently randomized 2:1 niraparib to investigator choice [eribulin, capecitabine, gemcitabine o

  11. Slide 11: Development Programs Update

    Development Programs Update Phase 3 NOVA trial continues to enroll patients Phase 3 BRAVO trial now screening patients Collaborating with SARC for Ewing’s sarcoma Niraparib Initial Phase 1 data presented at the European Cancer Congress and 15th World Conference on Lung Cancer Continuing evaluation o

  12. Slide 12: TSR-011: Significant Response and Stable Disease in Phase 1

    All three evaluable ALK+ NSCLC patients remain on study (as of 15 Oct 2013): One RECIST Partial Response (PR) Two Non-RECIST PRs (investigator assessed) Long term SD observed in papillary thyroid, pancreatic cancer and colorectal cancer patients without ALK expression The most frequently occurring D

  13. Slide 13: TRK gene rearrangements and TSR-011 binding and inhibition

    TRK gene rearrangements have been found in several tumor types, including lung cancers (NSCLC and LCNEC) and papillary thyroid cancer TRK expression is involved with tumor aggressiveness, metastatic potential, perineural invasion and pain Tumor Type TRK Mutations Prevalence Secretory breast ETVG-TRK

  14. Slide 14: Development Programs Update

    Development Programs Update Phase 3 NOVA trial continues to enroll patients Phase 3 BRAVO trial now screening patients Collaborating with SARC for Ewing’s sarcoma Niraparib Initial Phase 1 data presented at the European Cancer Congress and 15th World Conference on Lung Cancer Continuing evaluation o

  15. Slide 15: Rolapitant: Positive Phase 2 Results

    Complete Response Rate (%) * Statistically significant 1 CR: Complete Response 2 ST: Standard Therapy Rolapitant: Positive Phase 2 Results p = 0.032* p = 0.001* p = 0.045* Patients Experiencing No Significant Nausea (%) p = 0.029* p = 0.026* p = 0.005*

  16. Slide 16: Phase 3 Program Endpoints

    Phase 3 Program Endpoints Primary Endpoint: Complete Response (CR): no emesis and no use of rescue medication Secondary Endpoints: No emesis; no significant nausea Captured in daily diary, patient records Degree of nausea on validated VAS scale Clinical Endpoints in combination with other antiemetic

  17. Slide 17: Lonnie Moulder, Chief Executive Officer

    November 7, 2013 Lonnie Moulder Chief Executive Officer

  18. Slide 18: A Unique Therapeutic Profile

    1 Based upon the secondary endpoint of “No Significant Nausea”; P3 data (netupitant) and the product label (aprepitant, fosaprepitant) and P2 data (rolapitant). 2 Emend is a registered trademark of Merck & Co., Inc. 3 Netupitant is being developed by Helsinn Healthcare A Unique Therapeutic Profile P

  19. Slide 19: Established Guidelines Support Potential for NK-1 Market Growth

    Source: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive Established Guidelines Support Potential for NK-1 Market Growth HIGH EMETIC RISK INTRAVENOUS CHEMOTHERAPY – ACUTE AND DELAYED EMESIS PREVENTIONa,b,c Start before chemotherapyc,d Serotonin (5-HT3) antagonist:e,f Dolas

  20. Slide 20: $1.5B U.S. Market Opportunity

    1 A/C: anthracycline/cyclophosphamide $1.5B U.S. Market Opportunity Annual U.S. Opportunity: 5 Million “Day 1” Chemotherapy Administrations Approximately $300/Cycle Highly Emetogenic Regimens Moderately Emetogenic Regimens Cisplatin A/C1-based Lung Gynecological Genitourinary Head & Neck Others Brea

  21. Slide 21: Commercial Organization Design

    Commercial Organization Design Approximately 120 Total Headcount Opportunity for Significant Leverage

  22. Slide 22: Proven Commercial Strategy in CINV

    Proven Commercial Strategy in CINV Key Success Factors 1 3 2 4

  23. Slide 23: Corporate Goals

    Corporate Goals Initiated the Phase 3 trial of niraparib in ovarian cancer Presented niraparib Phase 1 data at ASCO Presented rolapitant DDI data at MASCC Begin the rolapitant IV dose finding and escalation study Present initial clinical data for TSR-011 at ECC Initiate patient treatment in the Phas

  24. Slide 24: Third-Quarter Operating Results

    Third-Quarter Operating Results November 7, 2013

TESARO — Q3 2013 Earnings Presentation on 6ix